Study: Diabetes risk rises with commonly used blood pressure drugs

Two new classes of blood-pressure medications are less likely to be associated with an increased risk of developing diabetes, especially among people already at risk, compared with some of the more commonly used blood pressure drugs, according to new research.

Researchers at Rush University Medical Center, Chicago, examined 22 clinical trials with more than 143,000 participants. While all of the participants had high blood pressure they did not have diabetes at the start of the trials. Angiotensin-receptor blockers and angiotensin-converting-enzyme, also known as ACE inhibitors, were less frequently associated with diabetes, as well as calcium-channel blockers, according to the study report. Beta blockers and diuretics, however, are most likely to precipitate diabetes, according to researchers, who noted that these type drugs are used most often to treat high blood pressure in the United States.

Nevertheless, a person's risk of getting diabetes while taking beta blockers and diuretics depends on a number of factors. Researchers determined that treatment of high blood pressure needs to be individually tailored. The study report was published in The Lancet.

More in News

Government agency launches health IT webpage for long-term care providers

Government agency launches health IT webpage for long-term ...

The Office of the National Coordinator for Health Information Technology has unveiled a new webpage with information and resources for long-term and post-acute (LTPAC) providers.

FDA responds to provider pressure, backs off stricter control of fecal transplants ...

Individuals with treatment-resistant Clostridium difficile can undergo fecal transplants after giving informed consent, the Food and Drug Administration recently announced. This is a victory for providers, who pushed back after the FDA recently announced it would tighten regulations around the transplants.

Judge denies Omnicare's 'untimely' motion to disqualify whistleblower in nursing home kickbacks ...

Omnicare has failed to disqualify a whistleblower who alleges the long-term care pharmacy paid kickbacks to nursing homes, ruled a district court judge.